Cantor Fitzgerald Predicts Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Gilead Sciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will earn $9.39 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $125.00 target price on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

GILD has been the topic of several other research reports. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Trading Down 2.6%

GILD stock opened at $110.09 on Tuesday. The company has a market capitalization of $136.94 billion, a PE ratio of 297.54, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences has a one year low of $62.69 and a one year high of $119.96. The company’s 50 day moving average price is $105.36 and its two-hundred day moving average price is $101.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) earnings per share. The firm’s revenue was down .3% on a year-over-year basis.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s payout ratio is presently 66.53%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,000 shares of company stock worth $4,630,310. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. 1248 Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter worth approximately $50,000. Fruth Investment Management bought a new stake in shares of Gilead Sciences during the 1st quarter valued at $237,000. First Hawaiian Bank lifted its stake in shares of Gilead Sciences by 1.3% during the 1st quarter. First Hawaiian Bank now owns 56,836 shares of the biopharmaceutical company’s stock valued at $6,368,000 after buying an additional 721 shares in the last quarter. Hodges Capital Management Inc. bought a new position in Gilead Sciences in the 1st quarter worth $190,000. Finally, Modern Wealth Management LLC boosted its holdings in Gilead Sciences by 24.4% in the 1st quarter. Modern Wealth Management LLC now owns 6,899 shares of the biopharmaceutical company’s stock worth $773,000 after buying an additional 1,351 shares during the period. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.